TEE
GYRE icon

Tibra Equities Europe’s Gyre Therapeutics GYRE Stock Holding History

Tibra Equities Europe’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-10,560
Closed -$343K – 113
2021
Q2 		$343K Buy
+10,560
New +$362K 0.11% 75
2018
Q2 		– Sell
-3,035
Closed -$587K – 149
2018
Q1 		$587K Buy
+3,035
New +$566K 0.1% 110

Other funds holding GYRE

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Tibra Equities Europe's GYRE Position: Q3 2021 in Review

Tibra Equities Europe sold out of Gyre Therapeutics (GYRE) in Q3 2021, closing a stake of 10,560 shares — an estimated $343K sold.

Tibra Equities Europe first reported a position in GYRE in Q1 2018 and held it in 2 quarters. The position peaked at $587K in Q1 2018. 65 funds tracked by Wall St. Rank hold GYRE as of Q3 2021.

  • Tibra Equities Europe reported no remaining Gyre Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Tibra Equities Europe sold 10,560 Gyre Therapeutics shares in Q3 2021, an estimated $343K.
  • Tibra Equities Europe first reported a position in Gyre Therapeutics in Q1 2018 and held it in 2 quarters.
  • Tibra Equities Europe's Gyre Therapeutics position peaked at $587K in Q1 2018.
  • 65 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q3 2021.

Based on Tibra Equities Europe's 13F filing for Q3 2021, filed 15 Nov 2021.